TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03571308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP + acalabrutinib
Description: Patient will be given R-CHOP and acalabrutinib
Study: NCT00822198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plantar vibration
Description: Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
Study: NCT01056549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
Study: NCT00475020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test dose = 32 mg/m\^2 by vein x 1 day; 100 mg/m\^2 by vein daily over 3 hours x 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 by vein daily over 1 hour x 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (ATG)
Description: 2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
Study: NCT03267056

Intervention type: DEVICE
Intervention: drug eluting balloon catheter (trade name: Orchid)
Description: use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
Study: NCT00586521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kogenate (BAY14-2222)
Description: One group two treatment schedules, first on-demand then switch to prophylaxis
Study: NCT02583542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
Study: NCT02311023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Study: NCT01600495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental TENS
Description: Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
Study: NCT01463280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tumescent lidocaine infiltration
Description: Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
Study: NCT05100758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Hexoses Correlated Compound
Description: Active Hexose Correlated Compound was isolated from basidiomycetes which comprise polysaccharides and amino acids.
Study: NCT04200508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted gown and gloves use
Description: Gown and glove use for high risk care activities in high risk residents
Study: NCT02668016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20mg tablets taken orally once daily for one month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally once daily for one month
Study: NCT04480736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 High dose
Description: JNJ-64281802 high dose will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Medium dose
Description: JNJ-64281802 medium dose will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Low dose
Description: JNJ-64281802 low dose will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Dosing Regimen X
Description: JNJ-64281802 dosing regimen X will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Dosing Regimen Y
Description: JNJ-64281802 dosing regimen Y will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Dosing Regimen Z
Description: JNJ-64281802 dosing regimen Z will be administered orally.
Study: NCT02106585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo
Study: NCT04146649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Description: Patients will receive a joint arthrocentesis to remove fluid from the joint.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Description: Patients will receive a joint arthrocentesis to remove fluid from the joint.
Study: NCT02260401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized report
Description: Each patient will receive an individualized report that contains their own outcome data for the first years of the LESS trial (including pain and function following treatment with epidural injections)
Study: NCT03021668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena Peel & Place Dressing
Description: Prevena Peel \& Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Closure of the Surgical Incision
Description: This would involve standard closure of the incision site
Study: NCT02486679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostin (PGE2) tablets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Study: NCT02976142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoimmunotherapy
Study: NCT01563848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of loop recorder
Description: The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of loop recorder
Description: The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
Study: NCT00480792

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GenHevac B Pasteur
Description: Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GenHevac B Pasteur
Description: Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GenHevac B Pasteur
Description: GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
Study: NCT03644784

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized protocol for assessing aortic regurgitation using videodensitometry
Description: Standardized protocol for assessing aortic regurgitation using videodensitometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized protocol for assessing aortic regurgitation using videodensitometry
Description: Standardized protocol for assessing aortic regurgitation using videodensitometry
Study: NCT03524547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J shaped stylet used for endotracheal intubation
Description: After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 60-degrees stylet used for endotracheal intubation
Description: After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
Study: NCT03788421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LIGASURE
Description: Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
Study: NCT00968981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: Three times weekly oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: Once weekly oral repeating dose
Study: NCT00829140

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10mg BID
Study: NCT03861299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake craniotomy
Description: Awake craniotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniotomy under general anesthesia
Description: Craniotomy under general anesthesia
Study: NCT00184717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.033 mg/kg/day of NN-220 for s.c. injection in cartridge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.033 mg/kg/day of NN-220 for s.c. injection in cartridge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.067 mg/kg/day of NN-220 for s.c. injection in cartridge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
Study: NCT02780141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral
Study: NCT04480671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Level III support procedure
Description: A level III support procedure is aimed at repairing the distal support of the vagina with either a posterior colporrhaphy and/or a perineorrhaphy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally Invasive Sacrocolpopexy
Description: All study participants are planning with their surgeon a minimally invasive sacrocolpopexy (robotic or laparoscopic) to repair pelvic organ prolapse.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Sacrocolpopexy
Description: All study participants are planning with their surgeon a minimally invasive sacrocolpopexy (robotic or laparoscopic) to repair pelvic organ prolapse.

Intervention type: OTHER
Group type: OTHER
Intervention: Transperineal ultrasound of the Pelvic Floor
Description: Subjects from either arm will be invited to participate in this exploratory arm of the study. If they choose to participate, they will have a preoperative ultrasound performed and an ultrasound performed at the time of their 6 month visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal ultrasound of the Pelvic Floor
Description: Subjects from either arm will be invited to participate in this exploratory arm of the study. If they choose to participate, they will have a preoperative ultrasound performed and an ultrasound performed at the time of their 6 month visit.
Study: NCT03494231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX06
Description: recombinant fully human anti-VEGFR2 monoclonal antibody against cancers
Study: NCT01071980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck
Description: Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
Study: NCT01185184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Single doses separated by a minimum of 72 hour washout between treatments
Study: NCT02339480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
Study: NCT02667964

Intervention type: OTHER
Group type: OTHER
Intervention: spiroergometry
Description: Spiroergometry on a bicycle ergometer

Intervention type: OTHER
Group type: OTHER
Intervention: spiroergometry
Description: Spiroergometry on a bicycle ergometer

Intervention type: OTHER
Group type: OTHER
Intervention: spiroergometry
Description: Spiroergometry on a bicycle ergometer
Study: NCT01858116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]ABY-025
Description: Intravenous injection followed by PET imaging
Study: NCT03937440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block with 'rocunium®'
Description: Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for post-tetanic count (PTC) in deep neuromuscular group.
Study: NCT03425448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin hemodialysis catheter lock solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neutrolin
Description: Neutrolin hemodialysis catheter lock
Study: NCT01309009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant oral solution
Description: Oral administration once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Nepadutant oral solution
Description: Oral administration once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant oral solution
Description: Oral administration once daily for 7 days
Study: NCT01000753

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT03788421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clamping and suturing
Description: Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
Study: NCT03596099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mizkan rice vinegar with acetic acid
Description: 200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
Study: NCT00771225

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fascial repair
Description: surgery to treat genital prolapse with fascia repair

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fascial repair
Description: surgery to treat genital prolapse with fascia repair

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mesh repair
Description: surgery to genital prolapse with mesh

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mesh repair
Description: surgery to genital prolapse with mesh
Study: NCT03596099

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mizkan rice vinegar without acetic acid
Description: 200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
Study: NCT04618601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is \>5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
Study: NCT01385358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopically Assisted Surgical Ablation
Description: Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
Study: NCT00674089

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Vitamin A 50,000 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin A Placebo
Study: NCT02079064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Inhalational anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous anesthetic that can be given by continuous infusion